PMID- 12787855
OWN - NLM
STAT- MEDLINE
DCOM- 20030829
LR  - 20181130
IS  - 0278-5846 (Print)
IS  - 0278-5846 (Linking)
VI  - 27
IP  - 4
DP  - 2003 Jun
TI  - Safety, effectiveness, and quality of life of olanzapine in first-episode 
      schizophrenia: a naturalistic study.
PG  - 667-74
AB  - OBJECTIVE: This study evaluated the effectiveness, safety, and quality of life 
      (Qol) offered by olanzapine in first-episode schizophrenia. METHOD: One hundred 
      and eighty-two patients with first-episode schizophrenia (ICD-10) drawn from a 
      larger, naturalistic, study were evaluated after 6 months of treatment with 
      olanzapine, risperidone, or conventional antipsychotics (CA). Clinical status was 
      assessed using the Clinical Global Impression-Severity (CGI-S) and Global 
      Assessment of Function (GAF). AWAD and EuroQol scales were used to evaluate 
      patients' attitude towards medication and Qol, respectively. RESULTS: Subjects 
      treated with olanzapine, risperidone, and CA showed similar improvements on CGI-S 
      and GAF. Treatment-emergent, extrapyramidal symptoms were significantly lower in 
      olanzapine-treated patients (17.8%) than in the risperidone (46.4%) and CA 
      (62.2%) groups. Compared to CA, olanzapine and risperidone showed significantly 
      greater improvement on the visual analog scale of EuroQol. Olanzapine-treated 
      patients also showed significantly improved AWAD scores. CONCLUSIONS: In 
      first-episode schizophrenia, atypical antipsychotics were effective, and improved 
      Qol. Olanzapine had a lower incidence of extrapyramidal symptoms and better 
      subjective acceptance of medication.
FAU - Montes, Jose Manuel
AU  - Montes JM
AD  - Centro de Salud Mental "La Plata" ("La Plata" Mental Health Center), University 
      of Alcala de Henares, Travesi;a de la Canada s/n Torrejon de Ardoz, 28850, 
      Madrid, Spain. j_m_montes@hotmail.com
FAU - Ciudad, Antonio
AU  - Ciudad A
FAU - Gascon, Josep
AU  - Gascon J
FAU - Gomez, Juan Carlos
AU  - Gomez JC
CN  - EFESO Study Group
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - England
TA  - Prog Neuropsychopharmacol Biol Psychiatry
JT  - Progress in neuro-psychopharmacology & biological psychiatry
JID - 8211617
RN  - 0 (Antipsychotic Agents)
RN  - 12794-10-4 (Benzodiazepines)
RN  - 3G0285N20N (Pirenzepine)
RN  - N7U69T4SZR (Olanzapine)
SB  - IM
MH  - Adult
MH  - Antipsychotic Agents/*adverse effects/*pharmacology
MH  - Attitude to Health
MH  - Basal Ganglia Diseases/chemically induced
MH  - Benzodiazepines
MH  - Female
MH  - Humans
MH  - Male
MH  - Olanzapine
MH  - Pirenzepine/*adverse effects/*analogs & derivatives/*pharmacology
MH  - *Quality of Life
MH  - Schizophrenia/*drug therapy
MH  - Severity of Illness Index
MH  - Treatment Outcome
EDAT- 2003/06/06 05:00
MHDA- 2003/08/30 05:00
CRDT- 2003/06/06 05:00
PHST- 2003/06/06 05:00 [pubmed]
PHST- 2003/08/30 05:00 [medline]
PHST- 2003/06/06 05:00 [entrez]
AID - S0278-5846(03)00077-0 [pii]
AID - 10.1016/S0278-5846(03)00077-0 [doi]
PST - ppublish
SO  - Prog Neuropsychopharmacol Biol Psychiatry. 2003 Jun;27(4):667-74. doi: 
      10.1016/S0278-5846(03)00077-0.